| abstract |
The use of a compound of the following general formula in the manufacture of a medicament for the treatment of an eye disorder: ** see formula ** where: R is hydrogen, C1-C8-alkyl, C3-C8-cycloalkyl, C1 -C6-alkylphenyl or a hydroxyl protecting group; R 1 and R 2 are independently from each other, hydrogen, C 1-C 6-alkyl, C 3-C 8-cycloalkyl, C 2-C 6-alkyl, C 1-C 6-alkoxy, C 2-C 6 -alkenyl, -S (O) q (C 1-C 6-alkenyl) or ** see formula ** and where A is -CH2-, -O-, -S-, -S (O) - or S (O) 2-: W 1 and W 2 are independently of each other, hydrogen, halo, hydroxyl, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio, C2-C4-alkenyl, or C2 -C4-alkylnil; R 3 is hydrogen, C 1-C 8-alkyl, C 3-C 8-cycloalkyl, C 1-C 6-alkylphenyl; X is O, S, or NR4; R 4 is hydrogen, C 1-C 6-alkyl, C 1-C 4-alkylphenyl, C 1-C 6-alkoxy; R 5 is hydrogen, C3-C8-cycloalkyl or C1-C8-alkyl; Y is chosen from and where Z 1 and Z 2 are independently from each other, hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, hydroxyl, C 2-C 4-alkenyl, C 2- C 6-alkyl; C 1-C 6-alkylthio, halo, trifluoromethyl or NR 6 R 7; R 6 and R 7 are independently of each other, hydrogen, C3-C8-cycloalkyl, C1-C6-alkyl, C1-C4-alkylphenyl; n is 1 to 6 inclusive m and p are independently of each other 0 to 6 both inclusive; q is 0.1 and 2, and the pharmaceutical salts thereof. |